However, conflicting data emerge, as Yen et al. highlighted, in their 2022 study, that the use of COX-2 inhibitors did not diminish the risk of developing skin cancer, and, even more so, it increased the BCC risk [59]. This evidence concerns the gene PTGS2 and skin cancer.